加速间歇性θ爆发刺激治疗难治性双相抑郁:一项随机临床试验
本随机临床试验于2022年3月至2024年2月纳入24例难治性双相障碍中重度抑郁发作患者,按1:1随机接受影像引导的活性或假加速间歇性θ爆发刺激,每日10次、连续5天,结果显示活性组治疗终点MADRS评分显著低于假刺激组。
要点
- 活性组治疗终点MADRS评分10.5(6.7)显著低于假刺激组25.3(6.7),估计差值-14.75(95%CI -19.73至-9.77;P<.001;Cohen d=-2.19)。
- 所有参与者均完成治疗及1个月随访。
- 作者结论认为aiTBS对难治性双相障碍抑郁症状的减轻比假刺激更有效。
核心结论
- 在这项随机临床试验中,aiTBS在减轻难治性双相障碍患者抑郁症状方面比假刺激更有效。
- 需要进一步试验来确定aiTBS的持久性并与其他治疗进行比较。
研究设计与样本
- 随机临床试验,于2022年3月至2024年2月开展,纳入从Penn双相门诊转诊的难治性双相障碍伴中重度抑郁发作个体。
- 纳入标准为:按抗抑郁治疗史表标准有2次或以上既往抗抑郁药试验失败、无其他主要精神科诊断、正在接受心境稳定剂治疗4周或以上、MADRS评分20分或以上。
- 治疗前使用静息态功能磁共振成像,通过计算与膝下前扣带皮层的连接性来确定个体化左侧背外侧前额叶皮层靶点。
- 患者按1:1随机接受影像引导的活性或假aiTBS,每日10次、连续5天、每小时1次,强度为90%静息运动阈值,总脉冲数90 000次。
- 共24例参与者(12例[50%]女性;12例[50%]男性;平均[SD]年龄43.3[16.9]岁)随机分配至活性组(n=12)或假刺激组(n=12)。
主要发现
- 所有参与者均完成治疗和1个月随访。
- 治疗终点时,活性组MADRS评分(基线平均[SD]30.4[4.8];治疗后10.5[6.7])显著低于假刺激组(基线28.0[5.4];治疗后25.3[6.7]),估计差值-14.75(95%CI -19.73至-9.77;P<.001;Cohen d=-2.19)。
关键数值与推荐
- 主要结局为治疗前后重复测量的MADRS评分。
- 活性组治疗终点MADRS评分10.5(6.7)vs 假刺激组25.3(6.7),估计差值-14.75(95%CI -19.73至-9.77;P<.001;Cohen d=-2.19)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者结论指出需要进一步试验来确定aiTBS的持久性并与其他治疗进行比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Bipolar disorder (BD) is chronic and disabling, with depression accounting for the majority of time with illness. Recent research demonstrated a transformative advance in the clinical efficacy of transcranial magnetic stimulation for treatment-resistant major depressive disorder (MDD) using an accelerated schedule of intermittent theta-burst stimulation (aiTBS), but the effectiveness of this treatment for treatment-refractory BD is unknown. OBJECTIVE: To evaluate the effectiveness of aiTBS for treatment-refractory BD. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial, conducted from March 2022 to February 2024, included individuals with treatment-resistant BD with moderate to severe depressive episodes referred from the Penn Bipolar outpatient clinic. Included patients had 2 or more prior failed antidepressant trials by Antidepressant Treatment History Form criteria and no other primary psychiatric diagnosis, were receiving a mood stabilizer for 4 or more weeks, and had a Montgomery-Åsberg Depression Rating Scale (MADRS) score of 20 or higher. INTERVENTION: Prior to treatment, resting-state functional magnetic resonance imaging was used to compute personalized left dorsolateral prefrontal cortex target by connectivity to subgenual anterior cingulate cortex. Patients were randomized 1:1 to 10 sessions per day of imaging-guided active or sham aiTBS for 5 days with 1 session per hour at 90% resting motor threshold for 90 000 pulses total. MAIN OUTCOME AND MEASURES: The main outcome was repeated MADRS scores before and after treatment. RESULTS: A total of 24 participants (12 [50%] female; 12 [50%] male; mean [SD] age, 43.3 [16.9] years) were randomized to active (n = 12) or sham (n = 12) aiTBS. All participants completed treatment and 1-month follow-up. MADRS scores were significantly lower in the active group (mean [SD], 30.4 [4.8] at baseline; 10.5 [6.7] after treatment) than in the sham group (28.0 [5.4] at baseline; 25.3 [6.7] after treatment) at treatment end (estimated difference, -14.75; 95% CI, -19.73 to -9.77; P < .001; Cohen d, -2.19). CONCLUSION AND RELEVANCE: In this randomized clinical trial, aiTBS was more effective than sham stimulation for depressive symptom reduction in patients with treatment-resistant BD. Further trials are needed to determine aiTBS durability and to compare with other treatments. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05228457.
引用
- Sheline YI, Makhoul W, Batzdorf AS, et al. Accelerated Intermittent Theta-Burst Stimulation and Treatment-Refractory Bipolar Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2024. PMID: 38985492. doi:10.1001/jamapsychiatry.2024.1787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。